Inhibitory activity of psilocybin/psilocin towards the enzymes of the cytochrome P450 (CYP450): an in vitro evaluation

Authors

  • A. M. Brito-da-Costa TOXRUN – Toxicology Research Unit, University Institute of Health Sciences (IUCS) – CESPU, Gandra, Portugal; UCIBIO/REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto, Portugal; Associate Laboratory i4HB – Institute of Health and Bioeconomy, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto, Portugal https://orcid.org/0000-0001-7327-1598
  • M. Silva-Carvalho TOXRUN – Toxicology Research Unit, University Institute of Health Sciences (IUCS) – CESPU, Gandra, Portugal; UCIBIO/REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto, Portugal; Associate Laboratory i4HB – Institute of Health and Bioeconomy, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto, Portugal
  • R. J. Dinis-Oliveira TOXRUN – Toxicology Research Unit, University Institute of Health Sciences (IUCS) – CESPU, Gandra, Portugal; UCIBIO/REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto, Portugal; Associate Laboratory i4HB – Institute of Health and Bioeconomy, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto, Portugal; Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal
  • Á. Madureira-Carvalho TOXRUN – Toxicology Research Unit, University Institute of Health Sciences (IUCS) – CESPU, Gandra, Portugal; LAQV/REQUIMTE, Laboratory of Pharmacognosy, Faculty of Pharmacy, University of Porto, Porto, Portugal
  • D. Dias da Silva TOXRUN – Toxicology Research Unit, University Institute of Health Sciences (IUCS) – CESPU, Gandra, Portugal; UCIBIO/REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto, Portugal; Associate Laboratory i4HB – Institute of Health and Bioeconomy, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto, Portugal

DOI:

https://doi.org/10.48797/sl.2023.63

Keywords:

Selected Oral Communication

Abstract

Background: Psilocybin is a hallucinogen produced by several “magic mushrooms” [1,2]. This prodrug is rapidly metabolized in the organism by alkaline phosphatases and esterases into psilocin, the active drug [1,2]. A scientific gap exists regarding the possible interactions between psilocybin/psilocin and CYP450 enzymes. Since the binding of drugs to CYP450 enzymes can interfere with the metabolism of other substrates leading to drug-drug interactions, this research topic is of utmost importance. Objective: This study aimed to assess potential inhibitory interactions between psilocybin/psilocin and CYP3A4, 2D6, 2B6 and 2A6. Methods: The in vitro assessment of CYP450 inhibition was performed using the Vivid®CYP450 screening kits, following the user’s guide. Concentrations of psilocybin and psilocin ranged between 1.14´10-13 - 4 mM and 6.1´10-5 - 1 mM for CYP3A4; 1.71´10-13 - 8 mM and 6.1´10-5 - 1 mM for CYP2D6; 2.4´10-4 - 8 mM and 2.4´10-5 - 1 mM for CYP2B6; and 3.8´10-6 - 2 mM and 7.6´10-8 - 1 mM for CYP2A6, respectively. Each test condition was mixed with baculosomes expressing the specific CYP, Vivid® regeneration system, NADP+, and a non-fluorescent substrate. Solvent and positive controls of inhibition, i.e., ketoconazole (CYP3A4), quinidine (CYP2D6), miconazole (CYP2B6) and tranylcypromine (CYP2A6,) were included. Fluorescence was measured for 60 minutes (Ex=415/20nm; Em=460/20nm) and the half-maximal inhibitory concentration (IC50) calculated using GraphPad prism 9.3.0. For CYP3A4 and 2D6 a minimum of three independent experiments were performed, and two independent experiments for CYP2A6 and 2B6. Results: For psilocybin, IC50 values of 49.43 mM (CYP3A4), >1000 mM (CYP2D6 and 2B6), and >300 mM (CYP2A6) were attained. For psilocin, the following IC50 values were obtained: 2.12 mM (CYP3A4), 11.89 mM (CYP2D6), 0.99 mM (CYP2A6) and 4.05 mM (CYP2B6). Conclusions: The results suggest a potential for psilocin to be an inhibitor of all the enzymes evaluated, especially CYP2A6, contrary to psilocybin which seems to only have the potential to inhibit CYP3A4. 

References

1. Brito-da-Costa, A. M.; Dias da Silva, D.; Madureira-Carvalho, Á.; Dinis-Oliveira, R. J., Psilocybin and magic mushrooms: Patterns of abuse and consequences of recreational misuse. In Handbook of Substance Misuse and Addictions, Patel, V. B.; Preedy, V. R., Eds. Springer Nature: Switzerland, 2022.

2. Dinis-Oliveira, R. J., Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev 2017, 49 (1), 84-91.

Downloads

Published

2023-04-21

How to Cite

Brito-da-Costa, A. M., Silva-Carvalho, M., Dinis-Oliveira, R. J., Madureira-Carvalho, . Á., & Dias da Silva, D. (2023). Inhibitory activity of psilocybin/psilocin towards the enzymes of the cytochrome P450 (CYP450): an in vitro evaluation. Scientific Letters, 1(Sup 1). https://doi.org/10.48797/sl.2023.63

Issue

Section

Oral Communications

Similar Articles

<< < 1 2 3 4 > >> 

You may also start an advanced similarity search for this article.